A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Authors: Ö. Türeci, Uğur Şahin, Henning Schulze‐Bergkamen, Zanete Zvirbule, Florian Lordick, Dieter Koeberle, Peter Thuss‐Patience, Thomas J. Ettrich, Dirk Arnold, Florian Bassermann, S-E. Al-Batran, Kai Wiechen, Karl Dhaene, Daniel Maurus, Michael A. Gold, Christoph Huber, Andrew Krivoshik, Ahsan M. Arozullah, J.W. Park, Martin Schüler - Annals of Oncology 2019 cited by 244